| Literature DB >> 31286706 |
Nicolina Goldschagg1,2, Tatiana Bremova-Ertl1,3, Stanislav Bardins3, Nora Dinca1, Katharina Feil1,3, Siegbert Krafczyk1, Stefan Lorenzl1, Michael Strupp1,3.
Abstract
BACKGROUND ANDEntities:
Keywords: falls; movement disorders; progressive supranuclear palsy; tauopathy; vestibular function
Year: 2019 PMID: 31286706 PMCID: PMC6620443 DOI: 10.3988/jcn.2019.15.3.339
Source DB: PubMed Journal: J Clin Neurol ISSN: 1738-6586 Impact factor: 3.077
Patient characteristics
| Patient no. | Age (years)/sex/symptom duration (years) | PSPRS score | FES score | Falls (per month) | DHI score | Medications |
|---|---|---|---|---|---|---|
| 1 | 76/male/4 | 30 | 20 | 2 | 40 | L-dopa |
| 2 | 79/male/5 | 19 | 19 | 0 | 10 | None |
| 3 | 75/female/4 | 38 | 61 | 8 | 58 | Amantadine, L-dopa |
| 4 | 65/male/4 | 34 | 44 | 7 | 68 | L-dopa |
| 5 | 77/female/6 | 23 | 41 | 1 | 84 | Acetyl-Dl-leucine |
| 6 | 67/female/1 | 45 | 36 | 2 | 84 | L-dopa, rotigotine |
| 7 | 64/female/2 | 30 | 41 | 7 | 52 | L-dopa |
| 8 | 65/female/2 | 10 | 24 | 2 | 48 | None |
| 9 | 74/female/4 | 28 | 53 | 4 | 68 | Donepezil |
| 10 | 75/female/5 | 43 | 46 | 2 | 76 | Rasagiline, L-dopa |
| 11 | 75/male/3 | 29 | 23 | m.d. | 46 | L-dopa |
| 12 | 72/female/2 | 13 | 33 | 0 | 36 | None |
| 13 | 78/male/2 | 43 | 40 | m.d. | 84 | None |
| 14 | 77/male/3 | m.d. | m.d. | 0 | m.d. | None |
| 15 | 78/female/6 | 43 | 44 | 1 | 68 | None |
| 16 | 67/male/4 | 34 | 24 | 6 | 38 | None |
| Mean±SD | 72.6±5.3/3.6±1.5 | 31±11 | 37±13 | 3±3 | 57±21 |
DHI: Dizziness Handicap Inventory, FES: Falls Efficacy Scale, m.d.: missing data, PSPRS: Progressive Supranuclear Palsy Rating Scale, SD: standard deviation.
Vestibular testing in patients with progressive supranuclear palsy
| Patient no. | Caloric testing | vHIT | oVEMP | cVEMP | |||||
|---|---|---|---|---|---|---|---|---|---|
| AR | Gain r | Gain l | Amp r | Amp l | AR | Amp r | Amp l | AR | |
| 1 | m.d. | 1.0 | 0.8 | 32.3 | 21.7 | 20 | 6.1 | 13.0 | 36 |
| 2 | 15 | 0.8 | 0.9 | 6.3 | 3.3 | 31 | 29.0 | 18.9 | 21 |
| 3 | m.d. | 1.2 | 1.2 | 26.4 | 21.5 | 10 | 45.3 | 38.1 | 9 |
| 4 | m.d. | 1.0 | 0.9 | 9.8 | 11.4 | 8 | 56.5 | 57.6 | 1 |
| 5 | 15 | m.d. | m.d. | 3.4 | 2.6 | 14 | 118.0 | 25.9 | 64 |
| 6 | m.d. | 1.1 | 1.0 | 15.7 | 15.1 | 2 | 38.9 | 49.2 | 12 |
| 7 | 6 | 1.1 | 0.9 | 9.0 | 10.0 | 5 | 40.5 | 43.8 | 4 |
| 8 | 11 | 1.0 | 0.8 | 19.6 | 19.6 | 0 | 88.4 | 96.8 | 5 |
| 9 | m.d. | 0.9 | 0.8 | 6.0 | 12.2 | 34 | 58.4 | 60.1 | 1 |
| 10 | 12 | 1.2 | 0.9 | 7.0 | 3.9 | 28 | 16.9 | 72.5 | 62 |
| 11 | m.d. | 1.1 | 1.1 | 13.7 | 17.3 | 12 | 80.5 | 83.9 | 2 |
| 12 | m.d. | 0.9 | 0.9 | 9.9 | 29.1 | 49 | 129.9 | 62.9 | 33 |
| 13 | m.d. | 1.1 | 1.1 | 13.4 | 11.5 | 7 | 176.5 | 195.5 | 5 |
| 14 | 7 | m.d. | m.d. | 14.5 | 22.8 | 22 | 50.6 | 79.8 | 22 |
| 15 | m.d. | 0.9 | 1.2 | 4.7 | 6.5 | 16 | 30.4 | 33.3 | 3 |
| 16 | 14 | 0.9 | 0.8 | 18.2 | 15.0 | 10 | 82.0 | 54.0 | 21 |
| Mean±SD | 1.0±0.1 | 0.9±0.1 | |||||||
Amp: amplitude, AR: asymmetry ratio, cVEMP: cervical vestibular evoked myogenic potential, l: left, m.d.: missing data, oVEMP: ocular vestibular evoked myogenic potential, r: right, SD: standard deviation, vHIT: video head impulse test.
VEMPs in patients with progressive supranuclear palsy
| oVEMP | cVEMP | |||||
|---|---|---|---|---|---|---|
| Patients | Controls | Patients | Controls | |||
| Reproducible ( | 16/16 | 16/17 | 16/16 | 16/17 | ||
| n1 latency (msec) | 11.9±3.4 | 11.9±2.8 | 0.897 | 25.3±3.5 | 24.8±2.8 | 0.669 |
| p1 latency (msec) | 16.9±3.7 | 17.2±3.3 | 0.985 | 17.4±3.1 | 15.9±2.5 | 0.094 |
| Absolute n1 Amp (µV) | 7.1±4.1 | 5.9±2.2 | 0.752 | 35.4±25.6 | 29.0±16.9 | 0.381 |
| Absolute p1 Amp (µV) | 7.1±3.5 | 6.8±3.8 | 0.867 | 27.6±16.0 | 26.1±16.6 | 0.305 |
| Absolute pp Amp (µV) | 13.5±7.2 | 12.5±5.6 | 0.752 | 63.4±40.4 | 54.1±32.7 | 0.287 |
| Corrected n1 Amp (µV) | 0.4±0.2 | 0.4±0.2 | 0.696 | 0.3±0.2 | 0.2±0.1 | 0.287 |
| Corrected p1 Amp (µV) | 0.4±0.3 | 0.5±0.3 | 0.724 | 0.2±0.1 | 0.2±0.1 | 0.491 |
| Corrected pp Amp (µV) | 0.8±0.5 | 0.9±0.6 | 0.616 | 0.6±0.3 | 0.5±0.2 | 0.305 |
Amp: amplitude, cVEMP: cervical vestibular evoked myogenic potential, oVEMP: ocular vestibular evoked myogenic potential, pp: peak-to-peak.
Video-oculography in patients with progressive supranuclear palsy and controls
| Patients | Controls | ||
|---|---|---|---|
| Saccades | |||
| Horizontal velocity for 30° stimulus (°/sec) | 34±92 | 442±66 | <0.001* |
| Downward velocity for 20° stimulus (°/sec) | 109±105 | 344±72 | <0.001* |
| Upward velocity for 20° stimulus (°/sec) | 121±110 | 348±78 | <0.001* |
| Horizontal amplitude for 30° stimulus (°) | 22±7 | 26±3 | 0.022* |
| Downward amplitude for 20° stimulus (°) | 9±8 | 18±3 | 0.005* |
| Upward amplitude for 20° stimulus (°) | 9±8 | 16±4 | 0.020* |
| Smooth pursuit at 0.1 Hz | |||
| Horizontal gain | 0.5±0.3 | 0.8±0.1 | 0.004* |
| Downward gain | 0.7±0.3 | 0.7±0.3 | 0.953 |
| Upward gain | 0.6±0.3 | 0.7±0.3 | 0.232 |
| Smooth pursuit at 0.2 Hz | |||
| Horizontal gain | 0.5±0.2 | 0.7±0.1 | 0.001* |
| Downward gain | 0.6±0.3 | 0.6±0.2 | 0.446 |
| Upward gain | 0.5±0.3 | 0.7±0.2 | 0.151 |
| Optokinetic nystagmus | |||
| Horizontal velocity for 10°/sec stimulus (°/sec) | 5.8±2.6 | 8.1±1.9 | 0.011* |
| Downward velocity for 10°/sec stimulus (°/sec) | 4.1±3.4 | 5.7±2.6 | 0.262 |
| Upward velocity for 10°/sec stimulus (°/sec) | 2.5±3.0 | 6.7±2.2 | 0.001* |
Data are mean±SD values.
*Significant difference between patients and controls with p<0.05.
Posturography results in patients with PSP and controls
| Eyes open, head straight | Eyes closed, head straight | Eyes open, head inclined 60° | Eyes open, foam-rubber platform | |||||
|---|---|---|---|---|---|---|---|---|
| Patients | Controls | Patients | Controls | Patients | Controls | Patients | Controls | |
| Not analyzable due to high assistance requirement | 0/16 | 0/16 | 0/16 | 0/16 | 1/16 | 0/16 | 4/17 | 2/16 |
| Sway path (total), m/min | 1.4±0.6 | 1.4±0.5 | 1.5±0.8 | 1.6±0.5 | 1.6±0.7 | 1.3±0.5 | 2.0±0.6 | 2.3±1.0 |
| 0.669 | 0.341 | 0.129 | 0.233 | |||||
| RMS (total), mm | 9.3±3.7 | 6.9±2.1 | 9.0±3.7 | 6.3±1.9 | 11.4±4.9 | 5.8±2.0 | 20.8±8.5 | 11.4±3.2 |
| 0.032* | 0.035* | <0.001* | <0.001* | |||||
| RMS (x), mm | 5.9±3.8 | 3.7±2.0 | 5.0±2.3 | 3.0±1.2 | 6.0±3.8 | 2.7±1.1 | 12.9±5.1 | 6.4±1.8 |
| RMS (y), mm | 7.0±2.4 | 5.6±1.5 | 7.1±3.3 | 5.5±1.8 | 9.7±4.1 | 5.0±2.0 | 15.1±9.4 | 9.4±2.9 |
| RMS (z), mm | 0.01±0.01 | 0.01±0.1 | 0.01±0.01 | 0.01±0.00 | 0.02±0.02 | 0.01±0.00 | 0.03±0.03 | 0.03±0.02 |
Data are n or mean±SD values. Total sway path did not differ significantly between patients and controls. The total RMS was significantly longer in PSP patients, especially during modulation of the somatosensory input when standing on foam-rubber platform.
*Significant difference between patients and controls with p<0.05.
PSP: progressive supranuclear palsy, RMS: root mean square, x: horizontal, y: anteroposterior, z: vertical.